head of the Sanofi Pasteur vaccines division at the French drugmaker. "Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...

Vaccines sales rose a currency-adjusted 25.5% to 3.8 billion euros in the quarter, ahead of a 3.2 billion euro analyst consensus. Sanofi is nearing a sale of a 50% stake in its consumer unit ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...